Colon Cancer Gut Bacterium Mystery Solved by Hopkins Team

Colon cancer gut bacterium research just got a plot twist: scientists at Johns Hopkins say they have finally found the docking point a common gut microbe uses to attack the colon, according to ScienceDaily. The study landed in Nature and solves a puzzle that has hung around for nearly two decades.

The microbe everyone has heard of, kind of

The bacterium is Bacteroides fragilis, which lives in the intestines of up to twenty percent of healthy people. Having it does not mean you will get cancer. Only certain strains make a toxin called BFT, and that toxin can wreck the colon's protective lining, spark chronic inflammation and encourage tumors to grow.

The link between the toxin and tumors was shown in a landmark 2009 study in Nature Medicine from senior author Cynthia Sears and her colleagues. Earlier work also showed BFT breaks down E-cadherin, a protein that helps hold neighbouring cells together. What nobody could explain was how the toxin first latched onto cells, because it did not seem to stick to E-cadherin directly.

A CRISPR hunt finds claudin-4

To crack it, MD/PhD candidate Maxwell White led a genome-wide CRISPR screen with Matthew Waldor's lab at Harvard Medical School. The team switched off genes one at a time in colon lining cells to see which ones the toxin needed. One gene stood out: the one that makes claudin-4, a protein that forms tight junctions, the seals between cells that guard the gut barrier.

When claudin-4 was knocked out, BFT could not bind and could not attack E-cadherin. "Claudin-4 was a clear, resounding top hit," White said, as quoted by ScienceDaily. Colleagues at the Molecular Biology Institute of Barcelona then showed in lab tests that one toxin molecule pairs with one receptor molecule.

Why the answer surprised scientists

Researchers had expected a signalling receptor, the kind cells use to respond to messages. Claudin-4 is a structural protein instead. BFT is also a protease, an enzyme that cuts other proteins, and most of those hit their targets directly. This one appears to need a separate receptor first, and the team could not find another toxin known to work that way, according to The Hindu BusinessLine.

The paper itself, titled "A pro-carcinogenic bacterial toxin binds claudin-4 to cleave E-cadherin," appears in volume six hundred fifty-four of Nature, and is listed through its Nature DOI record. Funding came from several sources, including the Bloomberg~Kimmel Institute for Cancer Immunotherapy, Cancer Research UK, the National Institutes of Health and the Howard Hughes Medical Institute. Co-authors came from Johns Hopkins, Harvard Medical School and the Barcelona institute, which shows how much teamwork a single receptor hunt can take.

Sears said the group had tried several times over the years to identify the receptor, calling the result an exciting moment. She added that understanding how bacterial toxins work can open doors to new detection and therapy approaches. That is a big claim for a lab result, but the mechanism is now concrete instead of a guess about a colon cancer gut bacterium.

A decoy that fooled the toxin in mice

Knowing the lock gave the team an idea: build a fake one. They made a soluble protein carrying claudin-4 sequences, designed to lure BFT away from the real colon cells. In mice, the toxin stuck to the decoy instead of the gut lining, and the animals were protected from BFT-induced damage.

White said the approach could be iterated with small molecules or other biologics that have better drug-like properties, and the group is now exploring which options work best.

What this does not prove yet

Here is the reality check. The mouse tests showed protection against tissue damage, not against colorectal cancer itself. Nobody has captured the exact three-dimensional structure of the toxin and receptor together, and even AlphaFold could not fully resolve it. Safety and effectiveness in people are still untested.

Still, interrupting a harmful process at its very first step is a different strategy from repairing damage afterward. The researchers say it could eventually support new ways to detect or treat conditions tied to bacterial toxins, including colorectal cancer, diarrhoea and bloodstream infections.

The big picture on the colon cancer gut bacterium story is simple: the lock is found, and the hunt for a key blocker is on. For a generation hearing more about colorectal cancer in younger adults, this is early but encouraging science, and a reminder that the microbiome is not just wellness hype. Follow more health coverage on GenZ NewZ and science stories as the follow-up studies arrive.